This Title All WIREs
How to cite this WIREs title:
Impact Factor: 9.957

Nanocarrier‐delivered small interfering RNA for chemoresistant ovarian cancer therapy

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Abstract Ovarian cancer is the fifth leading cause of cancer‐related death in women in the United States. Because success in early screening is limited, and most patients with advanced disease develop resistance to multiple treatment modalities, the overall prognosis of ovarian cancer is poor. Despite the revolutionary role of surgery and chemotherapy in curing ovarian cancer, recurrence remains a major challenge in treatment. Thus, improving our understanding of the pathogenesis of ovarian cancer is essential for developing more effective treatments. In this review, we analyze the underlying molecular mechanisms leading to chemotherapy resistance. We discuss the clinical benefits and potential challenges of using nanocarrier‐delivered small interfering RNA to treat chemotherapy‐resistant ovarian cancer. We aim to elicit collaborative studies on nanocarrier‐delivered small interfering RNA to improve the long‐term survival rate and quality of life of patients with ovarian cancer. This article is categorized under: RNA Methods > RNA Nanotechnology Regulatory RNAs/RNAi/Riboswitches > RNAi: Mechanisms of Action
Schematic illustration of drug resistance mechanism in ovarian cancer treatment
[ Normal View | Magnified View ]
Schematic diagram of nanocarrier‐mediated siRNA delivery and its mechanism of action
[ Normal View | Magnified View ]
Schematic diagram of working models of different types of RNA interference
[ Normal View | Magnified View ]

Browse by Topic

Regulatory RNAs/RNAi/Riboswitches > RNAi: Mechanisms of Action
RNA Methods > RNA Nanotechnology

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts